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Abstract 
 
Objectives: To critically review the literature on cost-effectiveness of cancer screening 
interventions, and examine incremental cost-effectiveness ratios (ICER) that may influence 
government recommendation on cancer screening strategies, and funding for mass 
implementation in Hong Kong health care system. 
Methods: We conducted a literature review of cost-effectiveness studies on Hong Kong 
population related to cancer screening published up to 2015, through hand search and 
database search of Pubmed, Web of Science, Embase, and OVID Medline. Binary data on 
government’s decisions were obtained from Cancer Expert Working Group, Department of 
Health. Mixed-effect logistic regression analysis was used to examine the impact of ICER on 
decision. Using Youden’s index, an optimal ICER threshold value for positive decision was 
examined by area under receiver operating characteristic curve (AUC). 
Results: Eight studies reporting 30 cost-effectiveness pairwise comparisons of 
population-based cancer screening were identified. Most studies reported an incremental 
cost-effectiveness ratio (ICER) of a cancer screening strategy versus comparator with 
outcomes in terms of cost per life-years (55.6%), or cost per quality-adjusted life-years 
(55.6%). Among comparisons with a mean ICER of USD102,931 (range: 800-715,137), the 
increase in ICER value by 1,000 was associated with decreased odds (odds ratios: 0.990, 
0.981-0.999; P=0.033) of positive recommendation. An optimal ICER value of USD61,600 
per effectiveness unit yielded high sensitivity of 90% and specificity of 85%.  
Conclusions: Linking published evidence to Government recommendations and practice on 
cancer screening, ICER influences the decision on the adoption of health technology in Hong 
Kong. Potential ICER threshold in Hong Kong may be higher than those of developed 
countries.  
 
Key Points for Decision Makers 
 An ICER threshold approach for policy decision making is common in developed 
countries but Research on the appropriate ICER threshold for positive decision in Hong 
Kong is lacking. 
 Linking published evidence to Government recommendations and practice on cancer 
screening, ICER influences the decision on the adoption of health technology in Hong 
Kong.  
 Potential ICER threshold for decision making of cancer screening in Hong Kong is 
USD$ 61,600 per effectiveness unit, beyond thresholds in other developed countries. 
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Manuscript 
 
Introduction 
 
Owing to the rapid development and increasing cost of health intervention, health economic 
evaluation is an essential approach to critically appraise the costs and benefits of new health 
interventions. Because of the limited healthcare resources, the integration of an emerging 
health intervention to healthcare system has to be well articulated with scientific justifications. 
From the perspective of health policy maker, the emerging health intervention not only has to 
be more effective than the conventional interventions but also good value for money. 
 
By principle, health economic evaluation is a scientific process of review and assessment. 
Emerging health interventions in the Western countries are primarily assessed by a single 
advisory body, for example, National Institute for Health and Care Excellence (NICE)[1] in the 
United Kingdom (UK), Pharmaceutical Benefits Advisory Committee (PBAC) in Australia, 
Canadian Agency for Drugs and Technologies in Health (CADTH) in Canada, and 
Pharmaceutical Management Agency (PHARMAC) in New Zealand. Such advisory bodies in 
respective countries often monitor the effectiveness and cost-effectiveness of emerging 
interventions in healthcare, and therefore provide national guidance and recommendation on 
the decision of whether the health intervention is likely to be accepted or rejected for 
implementation in routine clinical practice. The incremental cost-effectiveness ratio (ICER) of 
a new intervention relative to the conventional intervention against the country-specific 
threshold value is a critical determinant for decision making, while other practical 
considerations including budgeting and ethical issues are also taken into account. 
 
In Hong Kong, evaluations and recommendations on publically funded health interventions are 
not the responsibility of a single advisory body but different committees, depending upon the 
nature of the interventions. Drug Advisory Committee of Hospital Authority[2] has the role of 
recommending pharmaceutical interventions in Hospital Authority. Existing and new 
pharmaceutical interventions approved by Drug Advisory Committee are included in the 
Hospital Authority Drug Formulary[3] which has been initiated since 2005. Drugs in the 
formulary list are classified as general drugs with full government subsidy, special drugs with 
certain charges, and self-financing drugs. The health technology assessment process is subject 
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to challenge for a lack of transparency to the general public and documentation of the scientific 
bases for decision making [4]. Different committees were set up to review scientific evidence 
and offer recommendations for the prevention of communicable and non-communicable 
diseases. In field of cancer screening interventions, the Cancer Expert Working Group 
(CEWG)[5], under the Cancer Coordinating Committee, provides recommendations on suitable 
cancer prevention and screening measures at the population level.  
 
There is a growing body of health economic analyses that evaluated the health intervention 
utilized in the public sector of health services in Hong Kong and thereby compared with the 
ICER thresholds from other countries to inform decision making. However, ICER threshold 
adopted for comparison is rather diverse. Studies in UK adopted the threshold of GBP 20,000 - 
30,000 cost per quality-adjusted life year (QALY) gained suggested by NICE[1] whereas 
studies in the United States (US) adopted the benchmark of USD 50,000 per life-year or per 
QALY gain suggested by a cost-effectiveness analysis of hospital renal dialysis study in 
1992[6]. Countries are recommended to set their own ICER threshold to reflect how much they 
value for the gain in health of their populations, and to achieve appropriate drug pricing[7]. 
Although developed countries like the UK have adopted ICER thresholds, the ideal or widely 
accepted ICER threshold has yet to be established in Hong Kong or in mainland China by 
extension. One particular method[8] for threshold estimation is to infer the value of ICER 
threshold from the previous decisions, such that the relationship between the decision and 
ICER values of previous health interventions was applied to measure an overall threshold value 
over the past decision making processes. Alternative approach of setting the ICER threshold as 
three-fold of the national gross domestic product (GDP) per capita was recommended by the 
World Health Organization (WHO) [9]. However, no prior studies have been conducted for 
establishing such relationship. Research on the appropriate ICER threshold for 
recommendation and funding in Hong Kong is lacking.  
 
The aims of this study were to explore whether ICER values of cancer screening interventions 
were associated with decisions on recommending and/or accepting the interventions in Hong 
Kong, and to estimate the ICER thresholds applied by health policy makers on cancer screening 
in Hong Kong.  
 
Methods 
Running title: Impact of ICER on decision making in HK 
Page 5 of 20 
 
Literature Search on Health Technology Assessment in Hong Kong 
 
Search Engines and Strategies 
 
A systematic literature search was conducted in databases of PubMed, Web of Science using 
the Web of Knowledge platform, Embase, and MEDLINE using the Ovid searching platform to 
identify studies that investigated the economic evaluation of health interventions to be 
considered in public clinical setting in Hong Kong. The Medical Subject Heading “Hong 
Kong”, “China”, and “Chinese” were combined with “cost-effectiveness”, “cost-effective”, 
“cost-benefit”, “cost-utility”, “cost-minimization”, “cost-minimisation”, “cost-saving”, 
“willingness-to-pay” and “economic evaluation” (Appendix 1).  Studies were limited to 
English language, and the publication years to be between 1990 and 2015. The earliest year was 
chosen as 1990 because the concept of value for money in health emerged around 
early-1990s[10]. Additional hand search of google search engine was conducted to include the 
recent studies published in 2015 and past evidence from commissioned and non-commissioned 
reports to Food & Health Bureau, in case those reports were publicly available. If there were 
duplicated articles or reports, the most complete work done by authors was selected. After the 
initial check for duplicated articles, the abstracts of remaining articles were screened by authors 
(CW and BL) to exclude editorials, letters, commentaries, study protocols, case reports, pure 
literature reviews and meta-analyses, conference proceedings, past and current clinical 
guidelines, and recommendations.  
 
Inclusion and Exclusion Criteria 
 
After reviewing the full text of screened articles, the eligibility criteria of studies were (1) to 
involve the economic evaluations of cancer screening strategies against the status quo as the 
comparator, and (2) to evaluate the ICER of one screening strategy relative to the comparator. 
Articles without available full text or full report were excluded. Methodological quality of the 
included studies was assessed according to the Consolidated Health Economic Evaluation 
Reporting Standards (CHEERS) statement[11], which was adopted as the evaluation of 
reporting standard of health economics analysis. Articles that lack transparency and reporting of 
three essential items (Target population and subgroups, comparators, and measurement of 
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effectiveness) were further excluded from subsequent analyses. 
 
Data Extraction 
 
A standardized form was used when extracting the data reported in included studies. The 
primary data extracted from each article involved: first authorship, year of publication, design 
or type of economic evaluation, disease population (breast cancer, cervical cancer, colorectal 
cancer, liver cancer, gastric cancer, etc), frequency of screening, comparator of screening, 
targeted screening population, perspective, year cost, modelling characteristics, and 
cost-effectiveness outcomes. Modelling characteristics included type of models (Markov model, 
discrete-event simulation or no models), time horizons, discount rate, preference valuation for 
calculation of QALYs, and sensitivity analysis. Each health economic assessment of cancer 
screening strategy versus the comparator was defined as one comparative cost-effectiveness 
analysis. For each pairwise cost-effectiveness comparison, we obtained the ICER value at 
base-case scenario, as expressed in cost (USD) per life years gained, cost per QALYs gained, or 
cost per disability-adjusted life years (DALYs) averted of one screening strategy relative to the 
comparator. The ICER values expressed in Hong Kong dollar (HKD) were converted to USD 
as pegged in USD$1=HKD$7.8, and thus were not adjusted for year of valuation. Conclusion 
of included studies was grounded on the ICER value at base-case scenario, justifying the use of 
base-case ICER value. Studies that expressed ICER in other effectiveness units were excluded 
from subsequent retrospective analyses. In case when the ICER value was expressed in both the 
cost per life years gained and cost per QALYs gained in one comparison, cost per QALYs 
gained value was used as the ICER estimate in retrospective analyses.  
 
Past Decisions from Government 
 
Recommendations made by Cancer Expert Working Group (CEWG) on Cancer Prevention and 
Screening, Department of Health[5] were referred to the published clinical practice guidelines 
and recommendation report. As of the date of searching (January 2016) using the latest 
available data, decision of non-recommendation was assumed if the particular screening is not 
yet considered or recommended by the committee. Final decision to recommendation was 
recorded as binary outcomes of ‘Recommended’/‘Not recommended’. Decision of non-funding 
was assumed if the particular screening implemented to targeted population group is yet 
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supported by Department of Health and government bureau. Two mass cancer screening 
programmes have been officially recommended by Department of Health. Since 2004, CEWG 
has recommended regular pap smear screening[5] and implemented Cervical Screening 
Programme. Furthermore, CEWG recommended individuals aged 50-75 years to consider the 
colorectal cancer screening by faecal occult blood test every 1-2 years, sigmoidoscopy every 5 
years or colonoscopy every 10 years[5], and will thus implement the Colorectal Cancer 
Screening Pilot Programme in second half of 2016[12]. 
 
Statistical Analysis 
 
In retrospective analysis, effects of ICER on decisions (recommendation and/or funding) were 
tested by mixed-effect logistic regression models with the adjustment of multiple comparative 
cost-effectiveness analyses reported in each study. Equation of logistic regression model was 
specified as below:  
ln (Y / 1 – Y) = β0 + β1(ICER) + γ(STUDY) + ε 
where Y is dichotomous outcome variable, decision making; ICER is the continuous 
independent variable, ICER value; β0 and β1 are fixed-effect regression coefficients of 
intercept and ICER value, respectively; STUDY is the random-effect covariate; γ is the 
random intercept at the study level; and ε is the error term. 
 
Goodness-of-fit of model was assessed using log likelihood value and Wald χ2 test. An odds 
ratio (OR) of ICER below 1 indicated that the decrease in ICER was associated with higher 
odds of a recommendation or acceptance for funding than a negative decision. The predicted 
probability of recommendation or acceptance for funding was calculated for each ICER value. 
Sensitivity analysis was performed on the cost-effectiveness comparisons reporting ICER 
values in terms of cost per QALYs gained or cost per DALY averted, which incorporated both 
the quantity and quality of life in the effectiveness unit. 
 
Performance of each threshold cut-off value for positive decision in term of sensitivities and 
specificities was calculated. Sensitivity and specificity were defined as the probability of 
positive decision given the condition that the ICER value was less than threshold cut-off 
value, and the probability of negative decision provided that the ICER value was greater than 
threshold cut-off value. Youden’s index is the sum of sensitivity and specificity minus one 
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while the maximum value of Youden’s index was used for identification of an optimal ICER 
threshold value for positive decision. The receiver operating characteristic (ROC) curve was 
obtained by plotting sensitivity against one minus specificity for each ICER cut-off value. 
Discrimination of ICER value was examined by area under ROC curve (AUC). 
 
All statistical analyses were performed using STATA Version 13.0 (StataCorp LP. College 
Station, Tex). All significance tests were two-tailed and those with a p-value less than 0.05 will 
be considered statistically significant. 
 
Results 
 
Figure 1 lists the process of literature identification, abstract screening for eligibility, and 
selection of original studies during the literature and hand search presented in a Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses flow diagram[13]. Systematic 
database search was completed in March 2015 and identified a total of 1,335 potentially 
relevant studies (PubMed: 446; Web of Science: 232; MEDLINE: 300; and Embase: 357) that 
met the searching criteria in four research databases. After the removal of duplicated (n=644) 
and non-original articles (n=237) by abstract screening, the full-text of 70 studies were 
assessed for eligibility. Among them, 64 were not related to cancer screening and one did not 
report the ICER value considered as poor methodological quality. After the addition of four 
eligible studies by hand searching, nine[14-22] cost-effectiveness studies related to cancer 
screening were finally included in this review. The earliest study[14] that assessed 
comparative cost-effectiveness of cancer screening was published in 2004.  
 
Table 1 summarizes the characteristics of studies included in this review. This review 
identified 4 (44.4%) cost-effectiveness analyses and 5 (55.6%) cost-utility analyses which 
QALYs were used as the effectiveness unit of ICER value. Studies evaluated the cancer 
screening strategies designed for a wide range of disease population including colorectal 
cancer (33.3%), cervical cancer (22.2%), and breast cancer (22.2%). Source of clinical data 
were mostly adopted from purely published literature (66.7%) and cross-sectional data 
combined with literature data (22.2%). Most studies established a Markov modeling (88.9%), 
evaluated from perspective of healthcare provider (77.8%), and reported an ICER of a cancer 
screening strategy versus the comparator as outcomes in terms of cost per life-years (55.6%), 
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or cost per QALYs (55.6%). One study that reported the cases detected as effectiveness unit 
of ICER value was not considered in retrospective analysis. 
 
The retrospective analysis included eight studies have reported 30 cost-effectiveness pairwise 
comparisons of population-based cancer screening for colorectal (n=16, 53.3%), cervical 
(n=9, 30%), breast (n=4, 13.3%) and gastric cancers (n=1, 3.3%). General characteristics of 
the 30 pairwise comparisons and their respected decisions are shown in Table 2. Of the 30 
pairwise comparisons analyzed, 20 (66.7%) received a positive recommendation for 
implementation by CEWG, and 15 (50%) were accepted by government for routine use at the 
time of analysis. Seven comparisons reported in 3 studies expressed ICER value in term of 
both cost per life year gained and cost per QALYs gained, in which the latter was used in the 
retrospective analysis. No strategies were deemed to be cost-saving, leading to a negative 
ICER value, relative to comparator.  
 
Table 3 shows the effects of ICER value on past decision making of cancer screening 
strategies in retrospective analyses. Among comparisons with a mean ICER of USD 102,931 
(median: 19,166; range: 800 - 715,137), the mean ICER value was four-time higher for 
non-recommended cancer screening strategies than for those that was recommended by 
CEWG (USD 222,837 vs 42,978). Similarly, for acceptance of strategies for funding on 
routine use, the mean ICER for non-acceptance was 2.5-fold higher than that for acceptance 
(USD 160,766 vs 45,096). Mixed-effect logistic regression models depicted that the increase 
in ICER value by USD 1,000 was associated with decreased odds (OR: 0.990, 0.981-0.999; 
P=0.033) of positive recommendation. The ICER at which the predicted probability of 
positive recommendation was 50% was between USD 134,685 - 195,209. Although there is 
no significant association between the ICER value and funding decision for routine use, the 
predicted probability of funding decision varied with the ICER value. The ICER at which the 
cancer screening had a 50% chance of funding was between USD 72,534 - 134,685. Figure 2 
displayed the impact of ICER value on the predicted probabilities of positive decision that 
accepted for recommendation and funding. Sensitivity analysis using the cost-effectiveness 
comparisons reporting ICER value in terms of cost per QALY gained or cost per DALY 
averted demonstrated the estimated OR of less than one (OR: 0.995, 0.987-1.003; P=0.205), 
though not statistically significant. 
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Based on the Youden’s index, an ICER value of below USD 61,600 per effectiveness unit 
yielded a high sensitivity of 90% and specificity of 85% for positive recommendation. A 
lower ICER threshold value of below USD 8,044 was detected for positive decision of 
funding, with a sensitivity of 86.7% and a specificity of 73.3%. The ICER value yielded 
excellent discrimination for recommendation and funding, with an AUC of 0.890 (95% CI: 
0.770 – 1.000) and 0.822 (95% CI: 0.656 – 0.988), respectively. Figure 3 demonstrates the 
ROC curve and the optimal ICER threshold value for positive decision. 
 
Discussion 
 
The health technology assessment is a standardized process to assess the value of a new 
health care intervention and the ICER value is an important element to be considered in this 
process. In Hong Kong, the funded health interventions must be recommended by advisory 
body but the health interventions recommended by advisory body are not necessarily funded 
by the government bureau for implementation. The health technology assessment for 
recommending cancer screening strategies is conducted by CEWG while the government 
bureau has the final decision to launch mass population-based screening program for 
individuals. This review identified 9 published studies consisting of 30 cost-effectiveness 
comparisons assessing the cost-effectiveness of cancer screening interventions relative to 
status quo in Hong Kong. The small number of cost-effectiveness comparisons identified in 
this review implied the limited health economic evidence on the cancer screening 
interventions in Hong Kong, calling for further cost-effectiveness analyses of other 
controversial cancer screening such as ovarian cancer screening, prostate cancer screening 
and endometrial cancer screening.  
 
The retrospective analysis addressed two objectives 1) to examine whether the decision 
making of cancer screening strategies for recommendation or funding in routine clinical 
practice was based on the ICER value, and 2) to identify the ICER thresholds for previous 
decision on cancer screening in Hong Kong. In response to the first objective, findings reflected 
a significant relationship between the ICER values and the decisions to recommend cancer 
screening strategies by the CEWG, suggesting that the less ICER value of a cancer screening 
strategies had greater odds to be recommended by CEWG. Therefore, ICER value may play an 
important role of decision making during the health technology assessment of cancer screening 
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strategies in Hong Kong. This result was in line with reimbursement decision making in 
developed countries[23-28], prompting that the ICER is one of the most influential factors 
affecting the recommendation of interventions submitted to local advisory bodies during the 
health technology assessment. Besides health economic evidence, factors related to clinical 
effectiveness, treatment alternatives, disease severity, and study design of clinical trials are also 
taken into consideration by the advisory bodies during the health technology assessment[29, 
27].  
 
To address the second objective, an implicit ICER threshold may exist in Hong Kong context. 
Our retrospective analyses implied that a threshold for ICER value around USD 61,600 per 
one effectiveness unit gained to get a positive recommendation of cancer screening strategies 
in Hong Kong. Interestingly, one gastric cancer screening strategy[18] was not yet 
recommended despite the fact that its ICER value (USD 17,886) was two-fold less than 
potential ICER threshold value. One plausible explanation of negative recommendation was 
in part due to other multiple practical considerations. The procedure to make of previous 
decisions considers a variety of practical issues including not only health economic evidence 
but also public acceptance, appropriateness of screening tools for mass population-based 
screening, and capacity of healthcare system in coping with screening and positive screening 
results. The potential ICER threshold in present analysis was slightly higher compared to the 
benchmark value in UK (around GBP 20,000 – 30,000 per QALY gained) and the US (USD 
50,000 per life-year gained). In 2014, the per capita GDP in Hong Kong was around USD 
40,187[30]. According to the WHO recommendation suggesting an ICER value of one to 
three-fold of the per capita GDP as cost-effective [9], the threshold of ICER value in present 
study was somewhat surrounded by the threshold recommended by WHO but the 
effectiveness unit of WHO threshold is DALY, not interchangeable with QALY and LY. 
Therefore we urge to increase attention to the establishment of ICER threshold value for 
decision making in other health interventions such as vaccine and pharmaceutical 
interventions. However, there is premature to seek for overall cost-effectiveness threshold for 
positive decision of healthcare interventions in Hong Kong health care system. 
 
Our synthesized evidence revealed the lack in standardization of reporting of ICER values, 
year costs of resource unit or annual discount rate, as conformed to CHEERS checklist. For 
instance, the presentation of ICER value was typically expressed in either cost per life-year 
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gained or cost per QALY gained. Only 9 out of 30 (30%) pairwise comparisons expressed the 
ICER value in cost per QALY gained (Table 2), suggesting the need for evidence for 
preference or utility valuation in cancer health status to enable the QALY calculation. 
Furthermore, there was a paucity of cost-effectiveness studies alongside a cohort study, or 
from the societal perspective accounting for indirect cost incurred by patients and their 
caregivers. Only one study (11.1%) extrapolated the clinical data from cohort study to 
cost-effectiveness analysis but none of the effectiveness data were sourced from randomized 
controlled trials. In two studies adopting societal perspective, indirect cost was incorporated 
by estimating patient time including screening time and travel time. In order to present 
rationale and evidence to health policy makers and public society, future cost-effectiveness 
analyses are urged to adopt both the healthcare provider and societal perspectives. 
 
Limitations 
 
Discrepancies in effectiveness unit presented in included studies limited the interpretation of 
potential ICER threshold value identified in this review which adopted the life-year, QALYs 
or DALYs as effectiveness units. The potential ICER threshold value is interpreted with 
caution when the ICER value was estimated by other effectiveness units. Secondly, the 
potential ICER threshold value based on studies between 2004 and 2015 may not reflect the 
actual value in the future. Temporal trend on the ICER threshold was observed according to 
UK NICE’s decision making, suggesting the inflation of ICER threshold over time[27]. 
Thirdly, the health intervention may be recommended and funded with restrictions for use in 
European health care system. For example, the Scottish health technology assessment can 
accept the technology for either restricted use or routine use, and reject for use in NHS 
Scotland. However, there is no published data on whether the recommended or funded health 
intervention is under restricted use in Hong Kong. Dependent variables were only coded as 
binary fashion, collapsing ‘funded with restriction’ into ‘funded’ decision category. Fourthly, 
relevant factors influencing decision making and cost-effectiveness analysis were not 
controlled in retrospective analysis. Given the small number of cost-effectiveness 
comparisons and studies identified in this review, there was lacking in capacity to control for 
other relevant factors in retrospective analysis. Finally, the potential ICER threshold value 
was not generalizable to Chinese in other populations other than Hong Kong, and applied to 
any type of cancer screening in general.   
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Conclusion 
 
The ICER value may be one of the most important determinants of recommending mass 
cancer screening interventions by advisory body, but was not associated with implementation 
of population-based screening program in Hong Kong. Based on a critique of the evidence 
from cancer screening strategies, we found that ICER value may influence past decisions of 
health technology assessment in Hong Kong. Potential ICER threshold for what is considered 
a cost-effective intervention to be recommended in Hong Kong was established by this 
retrospective analysis, in which USD 61,600 per effectiveness unit was slighter beyond 
benchmark value in developed countries such as UK and US but surrounded by WHO 
recommended threshold based on one to three times annual GDP per capita.  
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Figure Legends 
 
Figure 1. PRISMA Flow Diagram of the literature search and selection process 
Figure 2. Impact of ICER value on the predicted probabilities of positive decision accepted 
for recommendation and funding  
Figure 3. Performance characteristics for each ICER cut-off value using receiver operating 
characteristic and the optimal ICER threshold value for positive decision 
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Table 1. Description and modeling characteristics of nine included studies  
  
        n (%)   n (%) 
Year of publication       Reporting of ICER     
2000-2005 1 (11.1) 
 
LY & QALY 3 (33.3) 
2006-2010 3 (33.3) 
 
LY only 2 (22.2) 
2011-2015 5 (55.6) 
 
QALY only 2 (22.2) 
Funding source 
 
 
 
Others 2 (22.2) 
Government 7 (77.8) 
 
Model type 
 
 
No funding 2 (22.2) 
 
Markov 8 (88.9) 
Industry 0 (0.0) 
 
No modelling 1 (11.1) 
Types of economic evaluation 
 
 
 
Time horizon 
 
 
Cost-effectiveness 4 (44.4) 
 
Lifetime 2 (22.2) 
Cost-utility 5 (55.6) 
 
50- or 60-year 3 (33.3) 
Disease population 
 
 
 
20- or 30-year 2 (22.2) 
Colorectal cancer 3 (33.3) 
 
5- or 15-year 2 (22.2) 
Cervical cancer 2 (22.2) 
 
Year cost 
 
 
Breast cancer 2 (22.2) 
 
2001-2010 5 (55.6) 
Colorectal, cervical & breast cancers 1 (11.1) 
 
Not reported 4 (44.4) 
gastric cancer 1 (11.1) 
 
Annual discount rate 
 
 
Target population 
 
 
 
3.0% 7 (77.8) 
Female only 5 (55.6) 
 
3.5% 1 (11.1) 
Age 50 or above 2 (22.2) 
 
Not reported 1 (11.1) 
Others 2 (22.2) 
 
Preference or utility valuation 
 
 
Study Perspective 
 
 
 
Yes by assumption  3 (33.3) 
Healthcare provider 7 (77.8) 
 
Yes by direct valuation 1 (11.1) 
Societal 2 (22.2) 
 
Yes by indirect valuation 1 (11.1) 
Both 0 (0.0) 
 
No QALY calculation 4 (44.4) 
Source of clinical data 
 
 
 
Sensitivity analysis 
 
 
Cohort data 1 (11.1) 
 
Deterministic 3 (33.3) 
Cross-sectional data & literature 2 (22.2) 
 
Probabilistic 5 (55.6) 
Literature only 6 (66.7)  No 1 (11.1) 
       Note: ICER=Incremental cost-effectiveness ratios; LY=life-year; QALY=quality-adjusted life-year 
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Table 2. Thirty cost-effectiveness pairwise comparisons of population-based cancer screening and their respected past decisions  
 
First 
author 
Year of 
publication Type of Cancer  Intervention 
Comparative arm 
(status quo) 
ICER 
(USD) 
  Decision making 
  
Recommen
dation[5] 
Year   Funding[5] Year 
Kim[14] 2004 cervical cancer Cytology screening every 5 years no screening 800   ✓ 2004  ✓ 2004 
Kim[14] 2004 cervical cancer Cytology screening every 4 years no screening 1,042 
 
✓ 2004 
 
✓ 2004 
Kim[14] 2004 cervical cancer Cytology screening every 3 years no screening 1,444 
 
✓ 2004 
 
✓ 2004 
Kim[14] 2004 cervical cancer Cytology screening every 2 years no screening 2,262 
 
✓ 2004 
 
✓ 2004 
Wong[15] 2015 colorectal cancer I-FOBT every 2 years no screening 2,976 
 
✓ 2013 
 
✓ 2016 
Wong[15] 2015 colorectal cancer I-FOBT every 1 year no screening 3,155 
 
✓ 2013 
 
✓ 2016 
Wong[15] 2015 colorectal cancer Colonoscopy every 10 years no screening 3,622 
 
✓ 2013 
 
X 
 
Kim[14] 2004 cervical cancer Cytology screening every 1 year no screening 4,739 
 
✓ 2004 
 
✓ 2004 
Wong[15] 2015 colorectal cancer G-FOBT every 2 years no screening 5,240 
 
✓ 2013 
 
✓ 2016 
Wong[15] 2015 colorectal cancer G-FOBT every 1 year no screening 5,871 
 
✓ 2013 
 
✓ 2016 
Tsoi[16] 2008 colorectal cancer FOBT every 1 year no screening 6,222 
 
✓ 2013 
 
✓ 2016 
Tsoi[16] 2008 colorectal cancer Colonoscopy every 10 years no screening 7,211 
 
✓ 2013 
 
X 
 
Woo[17] 2007 cervical cancer Pap smear screening every 5 years no screening 7,416 
 
✓ 2004 
 
✓ 2004 
Tsoi[16] 2008 colorectal cancer Sigmoidscopy every 5 years no screening 8,044 
 
✓ 2013 
 
X 
 
Wong[18] 2014 gastric cancer 
Helicobacter pylori screening and 
treatment for screening positive 
no screening *17,886 
 
X 
  
X 
 
Woo[17] 2007 cervical cancer Pap smear screening every 4 years no screening 20,447 
 
✓ 2004 
 
✓ 2004 
Woo[17] 2007 cervical cancer Pap smear screening every 3 years no screening 43,340 
 
✓ 2004 
 
✓ 2004 
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First 
author 
Year of 
publication Type of Cancer  Intervention 
Comparative arm 
(status quo) 
ICER 
(USD) 
  Decision making 
  
Recommen
dation[5] 
Year   Funding[5] Year 
Woo[17] 2007 colorectal cancer Colonoscopy every 10 years no screening 55,369 
 
✓ 2013 
 
X 
 
Wong[19] 2007 breast cancer Mammography screening every 2 years no screening 61,600 
 
X 
  
X 
 
Wong[20] 2012 breast cancer Mammography screening every 2 years no screening 72,534 
 
X 
  
X 
 
Woo[17] 2007 colorectal cancer Sigmoidscopy every 5 years no screening 108,879 
 
✓ 2013 
 
X 
 
Woo[17] 2007 breast cancer Mammography screening every 2 years no screening 109,155 
 
X 
  
X 
 
Woo[17] 2007 colorectal cancer Colonoscopy every 7 years no screening 113,616 
 
X 
  
X 
 
Woo[17] 2007 colorectal cancer 
FOBT every 1 year plus sigmoidscopy 
every 5 years 
no screening 134,685 
 
X 
  
X 
 
Woo[17] 2007 colorectal cancer Colonoscopy every 5 year5 no screening 195,209 
 
X 
  
X 
 
Woo[17] 2007 colorectal cancer Sigmoidscopy every 3 years no screening 276,414 
 
X 
  
X 
 
Woo[17] 2007 colorectal cancer FOBT screening every 1 year no screening 279,990 
 
✓ 2013 
 
✓ 2016 
Woo[17] 2007 colorectal cancer FOBT screening every 2 years no screening 291,499 
 
✓ 2013 
 
✓ 2016 
Wu[21] 2011 cervical cancer 
Pap smear screening every 1 year plus 
HPV DNA screening every 1 year 
Pap smear 
screening every 1 
year 
532,132 
 
X 
  
X 
 
Woo[17] 2007 breast cancer Mammography screening every 1 year no screening 715,138   X     X   
Note: ICER= incremental cost-effectiveness ratios; FOBT= fecal occult blood test; G-FOBT= guaiac FOBT; I-FOBT= immunochemical FOBT; 
HPV= human papillomavirus; 
* ICER value obtained from ‘'Screen and rescreen once' scenario for men 
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Table 3. Effects of ICER value on past decision making of cancer screening strategies by retrospective analysis 
           Recommendation 
 
  Odds ratio   Goodness-of-fit 
  Probability Estimate 95% CI P-value   
Log 
likelihood 
Wald 
χ2 P-value 
ICER value (in 1,000k) 66.7% 0.990 .981 - .999 0.033   -14.696 4.56 0.0328 
 
                
ICER value           -11.827 9.02 0.0027 
≤USD50,000 94.1% reference 
    
>USD50,000 30.8% 0.028 .003 - .288 0.003         
 
Acceptance 
 
  Odds ratio   Goodness-of-fit 
 
Probability Estimate 95% CI P-value   
Log 
likelihood 
Wald 
χ2 P-value 
ICER value (in 1,000k) 50.0% 0.993 .986 - 1.001 0.106   -18.547 2.61 0.106 
 
                
ICER value           -14.796 3.59 0.581 
≤USD50,000 76.5% reference 
 
   >USD50,000 15.4% 0.032 .001 - 1.125 0.058       
Note: ICER=Incremental cost-effectiveness ratios 
      
